Effect of Kang’ ai Injection (康艾注射液) on serum level of soluble interleukin-2 receptor and vascular endothelial growth factor in patients with esophageal carcinoma during radiotherapy

He Ze-feng; Wang  Jian-jun; Wang Wen-dong

doi:10.1007/s11655-006-0273-x

Your Location：

Home >

Browse articles >

Effect of Kang’ ai Injection (康艾注射液) on serum level of soluble interleukin-2 receptor and vascular endothelial growth factor in patients with esophageal carcinoma during radiotherapy

Updated：2021-08-27

- Effect of Kang’ ai Injection (康艾注射液) on serum level of soluble interleukin-2 receptor and vascular endothelial growth factor in patients with esophageal carcinoma during radiotherapy
- Chinese Journal of Integrative Medicine Vol. 12, Issue 4, Pages: 273-276(2006)
- Affiliations：
  
  Department of Thoraco-surgery, Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology,Wuhan,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-006-0273-x
  CLC：
- Published：2006，
Scan for full text
He, Zf., Wang, Jj. & Wang, Wd. Effect of Kang’ ai Injection (康艾注射液) on serum level of soluble interleukin-2 receptor and vascular endothelial growth factor in patients with esophageal carcinoma during radiotherapy., Chin. J Integ. Med. 12, 273–276 (2006). https://doi.org/10.1007/s11655-006-0273-x

He Ze-feng, Wang Jian-jun, Wang Wen-dong. Effect of Kang’ ai Injection (康艾注射液) on serum level of soluble interleukin-2 receptor and vascular endothelial growth factor in patients with esophageal carcinoma during radiotherapy. [J]. Chinese Journal of Integrative Medicine 12(4):273-276(2006)
He, Zf., Wang, Jj. & Wang, Wd. Effect of Kang’ ai Injection (康艾注射液) on serum level of soluble interleukin-2 receptor and vascular endothelial growth factor in patients with esophageal carcinoma during radiotherapy., Chin. J Integ. Med. 12, 273–276 (2006). https://doi.org/10.1007/s11655-006-0273-x DOI：

He Ze-feng, Wang Jian-jun, Wang Wen-dong. Effect of Kang’ ai Injection (康艾注射液) on serum level of soluble interleukin-2 receptor and vascular endothelial growth factor in patients with esophageal carcinoma during radiotherapy. [J]. Chinese Journal of Integrative Medicine 12(4):273-276(2006) DOI： 10.1007/s11655-006-0273-x.

摘要

To observe the effect of Kang’ ai Injection (康艾注射液

KAI) on serum level of soluble interleukin-2 receptor (sIL-2R) and vascular endothelial growth factor (VEGF) in patients with esophageal carcinoma (EC) during radiotherapy (RT)

and to investigate its synergistic effect with RT and its influence on immunological function of the body. One hundred and seventy patients with EC

who had missed the chance of surgical operational therapy

were assigned to the treated group (90 cases) and the RT group (80 cases)

and at the same time a control group consisting of 80 inpatients without tumors was set up. Patients in the RT group were treated with RT alone but KAI was given additionally to those in the treated group

with 50 ml given once per day via intravenous dripping

15 days as one course

and 2 courses administered in total. The immediate therapeutic efficacy and changes of serum sIL-2R and VEGF levels were observed

and the effect of KAI on patients’ quality of life (QOF) was evaluated by Karnofsky scoring. In 16 patients of the treated group it was completely remission (CR)

in 54 partially remission (PR)

in 18 it was stabilized disease (SD) and in 2 progressive disease (PD)

with the total effective rate (CR+PR) as 77.8%

while in those of the control group it was 12

4 and 72.5%

respectively

the immediate therapeutic efficacy in the treated group was somewhat better than that in the RT group

but showed no statistical significance (P>0.05). Serum levels of sIL-2R and VEGF in all the patients before treatment were higher than those in the control group

which were decreased after treatment in both groups (P<0.05)

but the improvement in the treated group was better than that in the RT group

showing significant difference (P<0.05)

and patients’ QOF improved more significantly in the former as well (62.2% vs 40.0%

P<0.05). KAI in combination with RT in treating patients with EC could enhance the immunological function of patients

improve their QOF and enhance their sensitivity to RT.

Abstract

To observe the effect of Kang’ ai Injection (康艾注射液

KAI) on serum level of soluble interleukin-2 receptor (sIL-2R) and vascular endothelial growth factor (VEGF) in patients with esophageal carcinoma (EC) during radiotherapy (RT)

and to investigate its synergistic effect with RT and its influence on immunological function of the body. One hundred and seventy patients with EC

who had missed the chance of surgical operational therapy

were assigned to the treated group (90 cases) and the RT group (80 cases)

with 50 ml given once per day via intravenous dripping

15 days as one course

and 2 courses administered in total. The immediate therapeutic efficacy and changes of serum sIL-2R and VEGF levels were observed

and the effect of KAI on patients’ quality of life (QOF) was evaluated by Karnofsky scoring. In 16 patients of the treated group it was completely remission (CR)

in 54 partially remission (PR)

in 18 it was stabilized disease (SD) and in 2 progressive disease (PD)

with the total effective rate (CR+PR) as 77.8%

while in those of the control group it was 12

4 and 72.5%

respectively

the immediate therapeutic efficacy in the treated group was somewhat better than that in the RT group

but showed no statistical significance (P>0.05). Serum levels of sIL-2R and VEGF in all the patients before treatment were higher than those in the control group

which were decreased after treatment in both groups (P<0.05)

but the improvement in the treated group was better than that in the RT group

showing significant difference (P<0.05)

and patients’ QOF improved more significantly in the former as well (62.2% vs 40.0%

P<0.05). KAI in combination with RT in treating patients with EC could enhance the immunological function of patients

improve their QOF and enhance their sensitivity to RT.

关键词

soluble interleukin-2 receptorvascular endothelial growth factoresophageal carcinomaradiotherapyKang’ ai Injectionsensitivity enhancing

Keywords

soluble interleukin-2 receptorvascular endothelial growth factoresophageal carcinomaradiotherapyKang’ ai Injectionsensitivity enhancing

references

Yamashita H, Nakagawa K, Tago M, et al. Treatment results of preoperative concurrent chemoradiotherapy followed by surgery for stage III or IV esophageal squamous cell carcinoma. Radiat Med 2006; 24(1):65–71.

Von Rahden BH, Stein HJ. Staging and treatment of advanced esophageal cancer. Curr Opin Gastroenterol 2005;21(4): 472–477.

Pannella A, Zambianchi M, Pezza A, et al. Quality of life in the aged after surgery. IV. Pathology of the esophagus. Minerva Chir 1994;49(3): 171–176.

Hejna M, Kornek GV, Schratter-Sehn AU, et al. Effective radiochemotherapy with cisplatin and etoposide for the management of patients with locally inoperable and metastatic esophageal carcinoma. Cancer 1996 15;78(8): 1646–1650.

Hassl JC, Meier R, Joller Je-melka B, et al. Serological immunomarkers in cutaneous T cell lymphoma. Dermatology 2004;209(4): 296–300.

Shi DZ, Li FR, Bartholomot B, et al. Serum sIL-2R, TNF-alpha and IFN-gamma in alveolar echinococcosis. World J Gastroenterol 2004; 10(24): 3674–3676.

Liu X, An H, Jiang Y. The level of soluble interleukin 2 receptor in esophageal carcinoma patients before and after radiotherapy. Chin J Oncol 1995; 17(2): 97–99.

McColl BK, Stacker SA, Achen MG, et al. Molecular regulation of the VEGF family—inducers of angiogenesis and lymphangiogenesis. APMIS 2004; 112(7–8): 463–480.

Ishikania M, Kitayama J, Kazama S, et al. The expression pattern of vascular endothelial growth factor C and D in human esophageal normal mucosa, dysplasia and neoplasia. Hepatogastroenterology 2004;51(59): 1319–1322.

Kleespies A, Guba M, Jauch KW, et al. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 2004;87(2): 95–104.

Wang L, Wang YP. Experimental study for the effect of TSPG on the expression of IL-3 in hematopoietic stromal cells. Acta Anat Sinica 2004; 24(1): 49–53.

Dai Q, Wang YP, Zhou KS, et al. Effect of ginseng polysaccharide on the proliferation and differentiation of granulocyte-monocyte progenitor cells. Basic Med Sci Clin 2004;24(1): 52–25.

Li G, Gao T, Wen J, et al. A research on quality of Radix Astragali. Chin J Chin Materia Medica 1992; 17(8): 454–456.

Ma LD, Zhagn Y, Wen SH, et al. Inhibition of tumor growth in tumor-bearing mice treated with matrine. Chin J Oncol 2000;27(6): 339–341.

FULL TEXT LINK

More>

Views

420

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Potential prevention: Aloe vera mouthwash may reduce radiation-induced oral mucositis in head and neck cancer patients

Celastrus Orbiculatus Extract inhibits tumor angiogenesis by targeting vascular endothelial growth factor signaling pathway and shows potent antitumor activity in hepatocarcinomas in Vitro and in Vivo

Effect of electro-acupuncture on tumor necrosis factor-α and vascular endothelial growth factor in peripheral blood and joint synovia of patients with rheumatoid arthritis

In Vitro antimetastatic effect of Changweiqing (肠胃清) through antiinvasion of hypoxic colorectal carcinoma LoVo cells

Effect of Fufang Xueshuantong Capsule (复方血栓通胶囊) on a rat model of retinal vein occlusion

Related Author

No data

Related Institution

Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari

Department of Physiology, School of Medicine, Showa University

Department of Image, 97th Hospital of People’s Liberation Army

Institute of Traditional Chinese Medicine and Western Medicine, School of Medicine, Yangzhou University

Nanjing University of Traditional Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰